Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 6.950

-1.1%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (3407)	6/10/2013 9:18:58 AM
From: richardred	of 7239

AstraZeneca in Deal for Pearl Therapeutics Worth Up to $1.15 Billion LONDON – The European drug maker AstraZeneca agreed on Monday to buy the American respiratory drug manufacturer Pearl Therapeutics for up to $1.15 billion. Under the terms of the deal, AstraZeneca will pay an initial $560 million for Pearl Therapeutics, based in Redwood City, Calif., whose products treat a number of respiratory diseases, including asthma. AstraZeneca will pay an additional $590 million if Pearl hits certain regulatory and sales targets, according to a statement from AstraZeneca. The latest acquisition is part of efforts by AstraZeneca, based in London, to restock its drug pipeline after its established products have come under threat from makers of generic drugs. AstraZeneca also bought the drug maker Omthera Pharmaceuticals last month for as much as $443 million to strengthen its cardiovascular business. Shares in AstraZeneca rose less than 1 percent in morning trading in London on Monday. The deal for Pearl Therapeutics is expected to close in the third quarter of 2013. dealbook.nytimes.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next